Qingjiang Chen

8PUBLICATIONS
8CO-AUTHORS
Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)ChemotherapyInnate immunityMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|May 28, 2026
LCP2 mediates SUV39H1-driven cellular senescence-related chemoresistance in natural killer/T-cell lymphoma.

|May 13, 2026
Prolonged intratumoral treatment with TLR7/8 agonist R848 regulates the tumor immune microenvironment resulting in enhanced antitumor activity.

|Jan 04, 2026
A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma.

Wanyue Zhao, Ling Li, Xiaorui Fu

|Dec 15, 2025
Identification of Aging-Related Hub Genes (ATP11B, RBBP7, DOCK10, and NUP160) as Potential Biomarkers and Therapeutic Targets in Sepsis.

Xueyi Sun, Shaolei Geng, Zeyuan Wang

|Jan 16, 2025
APOC1 inhibit NKTCL doxorubicin sensitivity by promoting mitophagy.

Sa Xiao, Jing Kuang, Jiamei Yang

|Feb 16, 2024
Gastrointestinal trichobezoars in the pediatric population: a retrospective study.

Linyan Wang, Yi Chen, Sai Chen

Pageof 2

Frequent Collaborators

3 joint publications

Mingzhi Zhang

2 joint publications

Xudong Zhang

1 joint publications

Yanjie Wang

1 joint publications

Donglin Liu